新股消息 | 应世生物拟港股上市 中国证监会要求补充说明股权变动与股东情况等事项

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for five companies, including Yingshi Biotechnology, which is preparing for an overseas listing. The CSRC has requested clarifications on various compliance and operational matters related to the company's offshore structure and shareholder changes [1][2]. Group 1: Compliance and Regulatory Requirements - The CSRC requires Yingshi Biotechnology to clarify the compliance of its offshore structure and return investment, including details on foreign exchange management, overseas investment, and tax management [1]. - The company must provide a legal opinion on the pricing basis, payment methods, and tax obligations related to the acquisition of domestic operating entities [1][2]. - The CSRC has requested a review of the stock option grants to external consultants and the legality of shareholder changes, particularly regarding any prohibited entities [2]. Group 2: Business Operations and Financials - Yingshi Biotechnology's business operations must be assessed to ensure they do not involve restricted areas such as human stem cells and gene therapy, and the company must confirm compliance with foreign investment policies [3]. - The company is required to supplement its filing with net asset data and clarify any inconsistencies in the issuance plan and prospectus [3][4]. - The product pipeline includes ifebemtinib, a selective FAK inhibitor nearing commercialization, and other innovative antibody-drug conjugates, indicating significant potential in cancer treatment [4].